MediPoint - Antibody-Drug Conjugates 2016 - Perspectives & Opportunities, Pipeline, Technology, Stakeholder & Business Analysis: ResearchMoz
Although the initial enthusiasm about antibody-drug conjugates has made room for a more realistic understanding, the prospects for success of ADC drug candidates remain good and are based on a well-filled pipeline, increasing adoption of next generation ADC technologies, lessons learned from failures, a balanced mixture of stakeholders and a variety of options for funding of ADC developments. About 70 ADCs are in clinical and pre-IND stages of development and at least the same number of ADC programs are in...
View full press release